Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,714 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FIX Clear all
Not listed Phase 4 Interventional

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris

NCT01448733
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 17, 2026, 10:20 PM EDT
Active, not recruiting Early Phase 1 Interventional

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

NCT05108298
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 39 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
347
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 215 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Not listed Phase 4 Interventional

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

NCT05863221
View directory record Official record
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Open-Label Phase III Long-Term Safety Trial of Liprotamase

NCT00449904
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
39
States / cities
Oakland, California • Denver, Colorado • Jacksonville, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

NCT02412111
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Results available

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Cardiovascular Disease, Major Depressive Disorder, Psychosis NOS
Interventions
Simvastatin, Losartan
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Repeated Oscillatory TMS Therapy of the Epileptogenic Cortical Area in Children With Focal CSWS

NCT04034030
View directory record Official record
Conditions
CSWS
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Terminated Not applicable Interventional Results available

Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients

NCT02296528
View directory record Official record
Conditions
Oropharyngeal Dysphagia (OPD), Dysphagia
Interventions
Swallowing Expansion Device
Device
Lead sponsor
Peter Belafsky, MD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

NCT01757405
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Recombinant Factor VIIa BI (rFVIIa BI)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Results available

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

NCT01443845
View directory record Official record
Conditions
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
217
States / cities
Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The TREFOIL Concept 5 Year Clinical Investigation

NCT02940353
View directory record Official record
Conditions
Edentulous or Failing Dentition Mandible
Interventions
TREFOIL concept
Device
Lead sponsor
Nobel Biocare
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

NCT01713439
View directory record Official record
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01163266
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 1 Interventional

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

NCT06995872
View directory record Official record
Conditions
Neuroblastoma
Interventions
rhIL-15, Dinituximab, Temozolomide, Irinotecan Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07759128
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

NCT02120300
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 17, 2026, 10:20 PM EDT
Completed No phase listed Observational

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy

NCT05044845
View directory record Official record
Conditions
Gene Therapy, Hemophilia B
Interventions
Interview
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years and older
Enrollment
150 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cerebral Blood Flow and Childhood Obstructive Sleep Apnea

NCT02995837
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Sleep Study, Neurocognitive Testing, CBF During Wakefulness, CBF During Sleep
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 12 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional

Education Session to Improve Program Adherence

NCT06428695
View directory record Official record
Conditions
Weight Management
Interventions
one-hour dietary self-monitoring tool education session
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 17, 2026, 10:20 PM EDT
Completed Not applicable Interventional Results available

Distal Targeter vs Free-hand

NCT05613257
View directory record Official record
Conditions
Femur Fracture, Tibial Fractures, Nonunion of Fracture, Nonunion of Fracture of Tibia, Nonunion of Fracture of Femur (Diagnosis), Tibia Fracture
Interventions
Distal targeting jig, Free-hand/perfect circles technique
Device · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 17, 2026, 10:20 PM EDT
Completed No phase listed Observational Results available

Restorelle Direct Fix Anterior and Posterior (A&P) for Female Pelvic Organ Prolapse: A Prospective Post Market Study

NCT01378065
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP)
Interventions
Restorelle Direct Fix A&P
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Baltimore, Maryland • Grand Rapids, Michigan • Marshall, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 17, 2026, 10:20 PM EDT